Stock GRI GRI BIOPAR
Add to a list
To use this feature you must be a member
Log inSign up

News GRI BIOPAR

Equities

GRI

US3622AW1069

Market Closed - Nasdaq
Other stock markets
 21:00:00 28/06/2024 BST 		5-day change 1st Jan Change
1.92 USD -2.04% Intraday chart for GRI BIOPAR -27.82% -71.34%
06-26 Wall Street Set to Open Marginally Lower Ahead of New Home Sales, GDP Figures MT
06-26 Top Premarket Decliners MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
GRI Bio Announces Closing of $4.0 Million Public Offering
AQ
GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators
AQ
GRI Bio Announces Pricing of $4 Million Public Offering
AQ
Wall Street Set to Open Marginally Lower Ahead of New Home Sales, GDP Figures
MT
Top Premarket Decliners
MT
Investors Await New Home Sales, GDP Data as US Futures Mixed in Wednesday's Premarket
MT
GRI Bio Files Shelf for Common Stock Sale
MT
GRI Bio Announces Reverse Stock Split
AQ
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference
AQ
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
AQ
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
AQ
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
AQ
GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
AQ
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
AQ
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
AQ
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
AQ
GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments
MT
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
AQ
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
AQ
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GRI Stock
  4. News GRI BIOPAR